XTR006 Tau PET for Alzheimer's Disease (NCT07115238)

Overview

XTR006 (also known as [18F]MK-6240 or Florquinitau) is a next-generation PET radiopharmaceutical designed to detect brain neurofibrillary tangles (NFTs) composed of hyperphosphorylated tau protein in living patients. The Phase 3 clinical trial (NCT07115238) evaluates the efficacy and safety of XTR006 PET visual assessment for detecting tau pathology in elderly subjects across the Alzheimer's disease spectrum["@mk6240"].

Overview

XTR006 (also known as [18F]MK-6240 or Florquinitau) is a next-generation PET radiopharmaceutical designed to detect brain neurofibrillary tangles (NFTs) composed of hyperphosphorylated tau protein in living patients. The Phase 3 clinical trial (NCT07115238) evaluates the efficacy and safety of XTR006 PET visual assessment for detecting tau pathology in elderly subjects across the Alzheimer's disease spectrum["@mk6240"].

This trial represents a critical advancement in Alzheimer's disease diagnostics, as tau PET imaging provides the unique ability to visualize the pathological hallmark that most closely correlates with cognitive impairment. Unlike amyloid plaques, which can be present decades before symptoms, tau pathology tracks closely with clinical disease severity and progression.

Trial Identification

| Parameter | Value |
|-----------|-------|
| NCT Number | NCT07115238 |
| Trial Name | XTR006 PET for Detection of Brain NFTs |
| Drug Name | XTR006 ([18F]MK-6240, Florquinitau) |
| Target | Neurofibrillary tangles (hyperphosphorylated tau) |
| Phase | Phase 3 |
| Status | Recruiting |
| Sponsor | Sinotau Pharmaceutical Group |
| Estimated Enrollment | 354 subjects |
| Start Date | 2024 |
| Completion Date | 2027 |

Study Design

Trial Type

This is a multicenter, Phase 3 clinical trial evaluating the efficacy and safety of PET visual assessment using XTR006 injection for detection of brain neurofibrillary tangles in elderly subjects.

Three-Disease Population Design

The trial enrolls participants across three distinct diagnostic categories:

1. Cognitively Normal Controls

| Characteristic | Criteria |
|---------------|----------|
| Clinical Dementia Rating (CDR) | 0 |
| MMSE Score | ≥28 |
| Amyloid PET | Negative |
| tau PET | Expected negative |

2. Mild Cognitive Impairment (MCI)

| Characteristic | Criteria |
|---------------|----------|
| Diagnosis | 2011 NIA-AA MCI criteria |
| Amyloid PET | Positive |
| tau PET | May be positive or negative |
| Cognitive concern | Subjective or objective |

3. Alzheimer's Disease Dementia

| Characteristic | Criteria |
|---------------|----------|
| Diagnosis | 2014 IWG-2 typical AD criteria |
| Amyloid PET | Positive |
| tau PET | Expected positive |
| Functional impairment | Present |

Intervention Protocol

All subjects receive:

• Single intravenous injection of 4-6 mCi XTR006
• Followed by 10 ml saline flush
• PET imaging at standardized timepoints (90-120 minutes post-injection)
• Brain uptake assessment using standardized protocols

Eligibility Criteria

Inclusion Criteria

Exclusion Criteria

Mechanism of Action

Tau Pathology in Alzheimer's Disease

Tau protein is a microtubule-associated protein that stabilizes neuronal cytoskeleton. In Alzheimer's disease, tau becomes hyperphosphorylated, leading to:

The progression of tau pathology follows a predictable pattern known as Braak staging[@braak2023]:

• Stage I-II: Transentorhinal region (early, clinically silent)
• Stage III-IV: Limbic region (correlates with MCI)
• Stage V-VI: Isocortical region (correlates with dementia)

XTR006 Binding Properties

XTR006 ([18F]MK-6240) is a second-generation tau PET tracer with optimized properties[@mk6240]:

First vs. Second-Generation Tau Tracers

| Property | First-Generation (Flortaucipir) | Second-Generation (MK-6240) |
|----------|--------------------------------|-----------------------------|
| Off-target binding | Higher (choroid plexus, basal ganglia) | Lower |
| Kinetic profile | Slower clearance | Faster clearance |
| Imaging window | 80-120 min | 90-120 min |
| Signal-to-background | Moderate | Higher |
| Specificity | Good | Excellent |

Clinical Applications of Tau PET

Diagnostic Utility

Tau PET imaging with XTR006 enables[@diagnostics2024]:

Prognostic Value

Tau burden correlates with:

• Clinical disease stage: Higher tau = more severe dementia
• Rate of progression: Elevated tau predicts faster decline
• Treatment response: Baseline tau affects anti-amyloid therapy response
• Life expectancy: Tau burden predicts survival in AD

Clinical Trial Enrichment

Tau PET is becoming essential for therapeutic trials:

Imaging Methodology

PET Acquisition Protocol

Standardized acquisition includes:

Quantification Approaches

SUVR (Standardized Uptake Value Ratio)

• Calculation: Target region SUV / Reference region SUV
• Reference region: Cerebellum gray matter (typically)
• Regions analyzed:
• Entorhinal cortex
• Hippocampus
• Inferior temporal
• Posterior cingulate
• Global cortical

Visual Assessment

• Trained readers: Nuclear medicine physicians
• Binary read: Positive vs. negative for tau
• Regional assessment: Pattern analysis (Braak-like staging)
• Clinical cutoffs: Established SUVR thresholds

Image Interpretation

Positive tau PET的特征:

• Elevated SUVR in temporal regions
• Regional pattern consistent with Braak staging
• Contrast with negative amyloid status (in controls)

• SUVR close to reference region
• No focal cortical uptake
• Pattern consistent with healthy aging

The ATN Classification Framework

The NIA-AA Research Framework uses biomarker-based classification[@atn2023]:

| Biomarker Category | Marker | Positive Indicator |
|-------------------|--------|-------------------|
| A (Amyloid) | Amyloid PET or CSF Aβ | Aβ42↓ or amyloid PET+ |
| T (Tau) | Tau PET or CSF p-tau | Tau PET+ or p-tau↑ |
| N (Neurodegeneration) | MRI, FDG PET, or CSF t-tau | Hip atrophy, hypometabolism, t-tau↑ |

Clinical phenotypes by ATN status:

• AD: A+T+N+ (typical AD)
• AD pathologic change: A+T-N-
• Alzheimer's disease with suspected non-AD pathology: A+T+N-

Rationale for Tau Imaging in Alzheimer's Disease

Amyloid vs. Tau

While amyloid-beta accumulation is considered the upstream trigger in the amyloid cascade hypothesis[@amyloid2023], tau pathology is the proximate cause of neuronal dysfunction:

| Feature | Amyloid-beta | Tau |
|---------|--------------|-----|
| Location | Extracellular plaques | Intracellular NFTs |
| Correlation with symptoms | Weak | Strong |
| Spreading | Less predictable | Braak staging |
| Therapeutic target | Anti-amyloid antibodies | Anti-tau therapies |

Why Tau PET Matters

Tau PET imaging provides unique value:

Comparison with Other Tau PET Tracers

Available and Development Tracers

| Tracer | Other Names | Company | Target | Status |
|--------|------------|---------|--------|--------|
| [18F]Flortaucipir | AV-1451, Tauvid | Avid Radiopharmaceuticals | 3R/4R tau (AD) | FDA approved |
| [18F]MK-6240 | Florquinitau, XTR006 | Sinotau/Merck | PHF-tau (AD) | Phase 3 |
| [18F]PI-2620 | - | Roche/Genentech | 4R tau (PSP, CBD) | Phase 2/3 |
| [18F]PM-PBB3 | - | Life Molecular | 3R/4R tau | Research |
| [18F]RO948 | - | Roche | PHF-tau (AD) | Phase 2 |

Clinical Considerations

• Flortaucipir: First FDA-approved tau PET, established clinical utility
• MK-6240: Improved off-target binding profile, better kinetics
• PI-2620: 4R tau binding, useful for PSP/CBD
• PM-PBB3: Broader tau isoform binding, research use only

Safety Considerations

Radiation Exposure

• Effective dose: ~3-4 mSv per scan
• Comparison: Similar to CT angiography
• Risk: Minimal for diagnostic indication

Adverse Events

Reported adverse events are typically mild:

• Injection site reactions: Rare
• Nausea: Uncommon
• Headache: Occasionally reported
• Dizziness: Rare

Contraindications

• Pregnancy: Contraindicated due to radiation
• Severe renal impairment: May affect tracer clearance
• Allergy to tracer components: Absolute contraindication

Statistical Considerations

Sample Size Justification

With 354 participants across three groups:

• Power: >90% to establish sensitivity and specificity
• Precision: Confidence intervals ±5% for each estimate
• Balance: ~118 subjects per diagnostic group

Primary Endpoints

Secondary Endpoints

• Brain uptake patterns (SUVR) across diagnostic groups
• Correlation with clinical measures (MMSE, CDR)
• Safety and tolerability assessment

Future Implications

If Successful

XTR006 approval would enable:

Competitive Landscape

Tau PET is becoming essential for AD clinical care:

• Approved: Flortaucipir (Tauvid) - 2020 FDA approval
• In development: MK-6240, PI-2620, others
• Research use: PM-PBB3, RO948

Integration with Amyloid PET

Combined amyloid and tau PET provides comprehensive in vivo pathology assessment:

| Amyloid Status | Tau Status | Interpretation |
|---------------|-----------|----------------|
| Negative | Negative | Normal aging or other dementia |
| Positive | Negative | Preclinical/prodromal AD |
| Positive | Positive | Alzheimer's disease dementia |

Biomarker Correlations

CSF Biomarkers

Tau PET correlates with CSF measures:

• p-tau181: Moderate correlation with cortical tau PET
• Total tau: Correlates with neurodegeneration markers
• Neurofilament light chain: Correlates with disease severity

Blood-Based Biomarkers

Emerging blood tests complement PET:

• p-tau217: Highly correlated with tau PET
• p-tau181: Good correlation with tau PET
• NfL: Correlates with disease progression

Regulatory Status

Current Approvals

• Flortaucipir (Tauvid): FDA approved (2020) for tau PET in AD
• Limited availability: Access restricted to specialized centers

XTR006 Development Pathway

• Phase 2: Completed, demonstrating safety and efficacy
• Phase 3: Ongoing (NCT07115238)
• Potential approval: 2028-2029 if successful

See Also

• [Tau Protein](/proteins/tau)
• [Neurofibrillary Tangles](/mechanisms/tau-pathology-pathway)
• [Tau PET Imaging](/biomarkers/tau-pet-imaging)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Amyloid PET Imaging](/biomarkers/amyloid-pet-imaging)
• [ATN Classification](/mechanisms/atn-biomarker-framework)
• [Braak Staging](/mechanisms/braak-staging-tau-pathology)
• [Sinotau Pharmaceutical](/companies/sinotau-pharmaceutical)

External Links

• [ClinicalTrials.gov: NCT07115238](https://clinicaltrials.gov/study/NCT07115238)
• [Sinotau Pharmaceutical](https://www.sinotau.com/)
• [Tau PET Imaging in AD](https://www.alz.org/research)

References

Pathway Diagram

The following diagram shows the key molecular relationships involving XTR006 Tau PET for Alzheimer's Disease (NCT07115238) discovered through SciDEX knowledge graph analysis: